Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Aug 2;4(8):e2118895.
doi: 10.1001/jamanetworkopen.2021.18895.

Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis

Chih-Hao Chen  1 , Chii-Yuan Huang  1   2 , Heng-Yu Haley Lin  1   3 , Mao-Che Wang  1   2 , Chun-Yu Chang  4 , Yen-Fu Cheng  1   2   5   6
Affiliations
Meta-Analysis

Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis

Chih-Hao Chen et al. JAMA Netw Open. .

Abstract

Importance: Platinum-induced ototoxic effects are a significant issue because platinum-based chemotherapy is one of the most commonly used therapeutic medications. Sodium thiosulfate (STS) is considered a potential otoprotectant for the prevention of platinum-induced ototoxic effects that functions by binding the platinum-based agent, but its administration raises concerns regarding the substantial attenuation of the antineoplastic outcome associated with platinum.

Objective: To evaluate the association between concurrent STS and reduced risk of ototoxic effects among patients undergoing platinum-based chemotherapy and to evaluate outcomes, including event-free survival, overall survival, and adverse outcomes.

Data sources: From inception through November 7, 2020, databases, including the Cochrane Library, PubMed, Embase, Web of Science, and Scopus, were searched.

Study selection: Studies enrolling patients with cancer who were undergoing platinum-based chemotherapy that compared ototoxic effects development between patients who received STS and patients who did not and provided adequate information for meta-analysis were regarded as eligible. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Data extraction and synthesis: The data were extracted by 2 reviewers independently. A random-effects model was used to explore objectives.

Main outcomes and measures: Relative risks (RRs) for ototoxic effects development and hemopoietic event development comparing the experimental group and the control group were estimated. Secondary outcomes were hazard ratios (HRs) for event-free survival and overall survival. Sensitivity analysis and trial sequential analysis were conducted to further consolidate pooled results.

Results: Among 4 eligible studies that were included, there were 3 randomized clinical trials and 1 controlled study. A total of 278 patients were allocated to the experimental group (ie, platinum-based chemotherapy plus STS; 158 patients, including 13 patients using contralatral ears of the control group as samples) or the control group (ie, chemotherapy; 133 patients, including 13 patients using contralateral ears of the experimental group as samples). Overall, patients who received STS had a statistically significantly decreased risk of ototoxic effects during the course of platinum-based chemotherapy (RR, 0.61; 95% CI, 0.49-0.77; P < .001; I2 = 5.0%) without a statistically significant increase in the risk of poor event-free survival (HR, 1.13; 95% CI, 0.70-1.82; P = .61; I2 = 0%) or overall survival (HR, 1.90; 95% CI, 0.90-4.03; P = .09; I2 = 0%). In the trial sequential analysis of event-free survival (z = -0.52) and overall survival (z = -1.68), although the cumulative z curves did not surpass the traditional significance boundary (-1.96 to 1.96 for both) or sequential monitoring boundary (event-free survival: -8.0 to 8.0; overall survival boundary not renderable in the analysis because the information size was too small) of the adjusted CI, they did not reach the required information size.

Conclusions and relevance: This meta-analysis found that concurrent STS delivery was associated with a decreased risk of platinum-induced ototoxic effects among patients treated with platinum-induced chemotherapy. These findings suggest that concurrent STS for protection against ototoxic effects should be considered for patients indicated for platinum-based chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None declared.

Figures

Figure 1.
Figure 1.. Overall Association of Sodium Thiosulfate (STS) With Prevention of Ototoxic Effects
IV indicates inverse variance method.
Figure 2.
Figure 2.. Event-Free Survival and Overall Survival
IV indicates inverse variance method; STS, sodium thiosulfate.
Figure 3.
Figure 3.. Subgroup Analysis by Delivery Route
IV indicates inverse variance method; NA, not applicable; STS, sodium thiosulfate.
Figure 4.
Figure 4.. Subgroup Analysis by Age Group
IV indicates inverse variance method; STS, sodium thiosulfate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fennell DA, Summers Y, Cadranel J, et al. . Cisplatin in the modern era: the backbone of first-line chemotherapy for non–small cell lung cancer. Cancer Treat Rev. 2016;44:42-50. doi:10.1016/j.ctrv.2016.01.003 - DOI - PubMed
    1. Aronson DC, Czauderna P, Maibach R, Perilongo G, Morland B. The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg. 2014;19(4):201-207. doi:10.4103/0971-9261.142001 - DOI - PMC - PubMed
    1. Gibson MK, Li Y, Murphy B, et al. ; Eastern Cooperative Oncology Group . Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057 - DOI - PubMed
    1. Armstrong DK, Bundy B, Wenzel L, et al. ; Gynecologic Oncology Group . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43. doi:10.1056/NEJMoa052985 - DOI - PubMed
    1. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378. doi:10.1016/j.ejphar.2014.07.025 - DOI - PMC - PubMed

Publication types